06:26 AM EST, 02/24/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported a Q4 non-GAAP net loss Monday of $0.07 per diluted share, widening from a loss of $0.04 a year earlier.

Analysts polled by FactSet expected a loss of $0.08.

The biopharmaceutical company did not report any revenue.

The company reported cash, cash equivalents and short-term investments of $412.3 million as of Dec. 31, up from $186.2 million a year earlier.

Summit shares were up nearly 11% in recent premarket activity